LeadArtis is currently funded by Growth Factor Biocapital, Bionexum Ventures and other angel investors as well as with non-dilutive grants.
R&D activities, facilities and equipment have been co-financed by the Spanish Ministry of Economy and Competitiveness (Torres Quevedo Program calls 2009, 2011, 2013 and 2017) and the RETOS Collaboration program 2014 and 2016 calls; by the RIS3 innovation program from the Comunidad de Madrid regional initiative; and by the 7th European Framework Program (FP7) in addition to private funds. Additionally, we have received support by the Genoma España Foundation and by the Carlos III Health Institute.

Latest News

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for...
LeadArtis project finalist of the Kaertor and J&J innovation award in recognition of its highly innovative R&D activity
The Kærtor Foundation together with Janssen (a Johnson & Johnson company) launched in 2018...
Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer...